[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中国实用外科杂志, 2020, 40: 121-138.
[2] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis, 2017, 65: 15-21.
[3] Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359: 926-930.
[4] Qu C, Wang Y, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy.Proc Natl Acad Sci U S A, 2019, 116: 6308-6312.
[5] Xu R, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat mater, 2017, 16: 1155-1161.
[6] Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature Commun, 2020, 11: 3475.
[7] Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut, 2019, 68: 2195-2205.
[8] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J clin oncol, 2011, 29: 4781-4788.
[9] Tan C, Cao J, Chen L, et al. Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma. Clin chem, 2019, 65: 905-915.
[10] Cho HJ, Eun JW, Baek GO, et al. Serum exosomal microRNA, miR-10b-5p, as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. J Clin Med, 2020, 9: 281.
[11] Zhou S, Wei J, Wang Y, et al. Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma. Exp Ther Med, 2020, 19: 2733-2740.
[12] Qi L, Xiang B, Wu F, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular Carcinoma. Cancer Res, 2018, 78: 4731-4744.
[13] Hu Y, Ulrich BC, Supplee J, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res, 2018, 24(18): 4437-4443.
[14] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol, 2020.Online ahead of print. |
